ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Effect of ERN1 knockdown on the expression of MAP3K5, MAP4K3, CIB1, RIPK1, and RIPK2 genes in U87 glioma cells and its hypoxic regulation

Dmytro O Minchenko, Taia V Bakalets, Daria O Tzymbal, Oksana O Ratushna, Yulia M Bashta, Olelsandr O Minchenko.




Abstract

ERN1 (endoplasmic reticulum to nucleus signaling 1)-mediated signaling pathway plays an important role in glioma growth. We studied the possible role of protein kinases MAP4K3, MAP3K5, RIPK1, and RIPK2 as well as protein kinase interacting protein CIB1 in suppression of U87 glioma cell proliferation upon ERN1 knockdown. It was shown that blockade of ERN1 signaling enzyme function significantly decreases the expression level of genes encoding MAP4K3, RIPK2, and CIB1 in U87 glioma cells, but increases expression of RIPK1 gene. At the same time, the blockade of ERN1 signaling enzyme does not affect the expression of MAP3K5 gene in glioma cells. Hypoxia down-regulates the expression level of MAP3K5, MAP4K3, RIPK1, and RIPK2 mRNAs in control glioma cells. However, inhibition of ERN1 affected hypoxia-mediated changes in expression of these kinase genes and their magnitude. Results of this investigation clearly demonstrated that the expression of MAP4K3, RIPK1, RIPK2, and CIB1genes in U87 glioma cells in human U87 glioma cells relies on blockade of ERN1-mediated endoplasmic reticulum stress signaling and is mostly down-regulated by hypoxia in dependence of ERN1 enzyme function.

Key words: mRNA expression, ERN1 knockdown, MAP4K3, RIPK1, hypoxia, U87 glioma cells







Bibliomed Article Statistics

11
20
16
22
29
30
22
R
E
A
D
S

4

12

12

24

13

17

6
D
O
W
N
L
O
A
D
S
10111201020304
20242025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.